Research suggests that oncogene S100A10 may play a definitive role in the progression of ovarian cancer and its expression levels may affect sensitivity to carboplatin.
Researchers compared primary high grade serous ovarian carcinoma tumors and their matched metastasis, showing evidence of separating the 2 sample types and potentially predicting patient survival.
Dr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.
The approval comes one day after the FDA approved niraparib for the same subset of ovarian cancer.
Niraparib was approved by the (FDA) for previously treated advanced ovarian, fallopian, or primary peritoneal cancers.
The clear cell histologic subtype of stage I ovarian cancer is associated with a disproportionately high risk for capsule rupture during surgery compared with other histologies.
A new study found a link between posttraumatic stress disorder and ovarian cancer.
Combination therapy with nivolumab and bevacizumab appeared to have clinical activity in ovarian cancer patients with platinum-sensitive or platinum-resistant disease.
A new study looked at trametinib's effect on survival and response rates in ovarian cancer.
The results of the first therapy to use a PARP inhibitor with chemotherapy for patients with ovarian cancer were presented at ESMO Congress 2019.